Welcome to our dedicated page for Quidel SEC filings (Ticker: QDEL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The QuidelOrtho Corporation (Nasdaq: QDEL) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As an issuer in the in vitro diagnostics and medical device manufacturing space, QuidelOrtho uses these filings to report on its financial condition, capital structure, material agreements and other significant events.
Investors can review current reports on Form 8‑K, where QuidelOrtho furnishes press releases announcing quarterly financial results, earnings conference calls and stockholder letters discussing recent performance and strategic priorities. For example, 8‑K filings in November 2025 reference third‑quarter results and a stockholder communication, while an August 21, 2025 8‑K details a Credit Agreement that established senior secured term loan A and term loan B facilities and a revolving credit facility with a syndicate of lenders.
Alongside 8‑Ks, users can also access annual reports on Form 10‑K and quarterly reports on Form 10‑Q, which provide more comprehensive information on QuidelOrtho’s business, including its diagnostic segments in clinical chemistry, immunoassay, immunohematology and molecular testing. These reports typically include discussions of risk factors, research and development spending, and other elements that shape the company’s long‑term outlook.
For those interested in governance and ownership, proxy statements and beneficial ownership reports (such as Forms 3, 4 and 5) can be used to analyze executive and director holdings and transactions, although specific examples are not detailed here. Together, these documents form a record of how QuidelOrtho communicates with regulators and investors about its operations and capital decisions.
Stock Titan enhances this information by pairing real‑time EDGAR updates with AI‑powered summaries that explain the key points of long filings in plain language. Users can quickly see what each new 10‑K, 10‑Q, 8‑K or Form 4 means for QuidelOrtho without reading every page, while still having direct access to the full text for deeper review.
QuidelOrtho Corporation has issued its definitive proxy for the 2026 virtual annual meeting on June 16, 2026. Stockholders will vote on electing 10 directors for one-year terms, an advisory Say‑on‑Pay resolution on executive compensation, and ratifying KPMG as independent auditor for the fiscal year ending January 3, 2027.
The company highlights strong 2025 execution as it shifts from COVID‑driven volatility toward a more durable diagnostics mix, with revenue of $2.73 billion, including $2.33 billion from non‑respiratory products and $402 million from respiratory products. Adjusted EBITDA margin reached 22% as GAAP operating expenses fell 5% through cost‑savings initiatives.
The Board emphasizes robust governance, with an independent Chair, majority‑independent Board and fully independent committees, annual director elections, and stock ownership requirements for directors and executives. It recommends voting FOR all director nominees, FOR the Say‑on‑Pay proposal, and FOR ratifying KPMG.
QuidelOrtho Corp Chief Operations Officer Philip D. McLellan reported routine equity compensation activity. On April 22, 2026, 3,238 restricted stock units vested and were released into an equal number of common shares. The company withheld 1,162 of those shares at a price of $11.90 per share to cover tax obligations, a non‑market disposition. After these transactions, McLellan directly held 22,412 common shares. An additional 3,238 restricted stock units are scheduled to vest on April 22, 2027.
QuidelOrtho Corp executive Bryan Michael Hanson reported routine equity compensation and related tax withholding. On April 22, 3,508 restricted stock units previously reported on a Form 3 were released and converted into 3,508 shares of common stock. To cover tax withholding obligations, 1,269 shares were disposed of through the issuer’s share withholding at $11.90 per share, rather than an open‑market sale. Following these transactions, Hanson directly held 4,408 common shares. An additional 3,508 restricted stock units remain scheduled to vest on April 22, 2027, each representing the right to receive one share of QuidelOrtho common stock.
SISITSKY NATHANIEL reported acquisition or exercise transactions in this Form 4 filing.
QuidelOrtho Corp granted its Chief Legal Officer, Nathaniel Sisitksy, new equity awards reported as compensation. He received 73,434 non-qualified stock options exercisable at $17.49 per share, expiring on April 15, 2036, covering 73,434 shares of common stock. He was also granted 73,435 restricted stock units, each representing one share of common stock. For these awards, 24,478 shares are scheduled to vest in equal installments on April 15, 2027 and April 15, 2028, with 24,479 shares vesting on April 15, 2029, and another schedule provides 24,478 shares vesting in equal installments on April 15, 2027, April 15, 2028 and April 15, 2029.
QuidelOrtho Corporation released preliminary unaudited results showing first quarter 2026 revenue of $615–$620 million, reflecting a weaker respiratory season, slower distributor sales in China tied to proposed reimbursement cuts, and EMEA order delays related to the Middle East conflict.
The company expects first quarter 2026 free cash flow of $(65) to $(70) million and continues to anticipate positive free cash flow for full-year 2026. Management believes the low end of its previously issued full-year 2026 financial guidance remains achievable and plans to discuss this outlook with full results on May 5, 2026.
T. Rowe Price Investment Management, Inc. filed an amended Schedule 13G disclosing beneficial ownership of 5,629,965 shares of QuidelOrtho Corp common stock, equal to 8.3% of the class. The filing lists 5,612,705 shares with sole voting power and 5,629,965 shares with sole dispositive power. The amendment is signed by a Vice President and dated 04/08/2026.
QuidelOrtho Corp executive Nathaniel Sisitsky, the Chief Legal Officer, has filed an initial ownership report indicating that he currently holds no securities beneficially owned in the company. The filing shows total direct holdings of 0 shares following the reported position.
QuidelOrtho Corp Chief Financial Officer Joseph M. Busky reported routine equity compensation activity involving restricted stock units and related tax withholding. On the transaction date, 4,925 restricted stock units were released, converting into 4,925 shares of common stock as part of previously reported awards.
Of these shares, 1,519 were withheld by the company at $14.78 per share to satisfy tax withholding obligations tied to the RSU release, which is not an open-market sale. Following these transactions, Busky held 44,818 shares of common stock directly and 10,290 shares indirectly through a trust.
QuidelOrtho Corp received an amended Schedule 13G/A from The Vanguard Group stating that, following an internal realignment, Vanguard reports 0 shares beneficially owned of QuidelOrtho common stock.
The filing explains certain subsidiaries will report disaggregated ownership separately in reliance on SEC Release No. 34-39538.